Osteoprotegerin levels in patients with severe mental disordersCytokines as new treatment targets in chronic heart failureThe complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosisInterleukin-7-mediated inflammation in unstable angina: possible role of chemokines and plateletsIncreased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammationSimilar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factorInterleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorderToll-like receptor 9-activation during onset of myocardial ischemia does not influence infarct extensionIncreased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failureStatins affect the presentation of endothelial chemokines by targeting to multivesicular bodiesExcessive innate immune response and mutant D222G/N in severe A (H1N1) pandemic influenza.Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure.Peripheral endothelial dysfunction in heart transplant recipients: possible role of proinflammatory cytokines.Vitamin D Status and Long-Term Mortality in Community-Acquired Pneumonia: Secondary Data Analysis from a Prospective Cohort.The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial.Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients.Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events.Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes.Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF).Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency.Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in patients with neuroendocrine tumors.Differences in insulin sensitivity, lipid metabolism and inflammation between young adult Pakistani and Norwegian patients with type 2 diabetes: a cross sectional study.Toll-Like Receptor 9 Promotes Survival in SERCA2a KO Heart Failure Mice.A salmon protein hydrolysate exerts lipid-independent anti-atherosclerotic activity in ApoE-deficient miceElevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function.Associations of brain-natriuretic peptide, high-sensitive troponin T, and high-sensitive C-reactive protein with outcomes in severe aortic stenosis.Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics.Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathyLack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overloadSun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis.Toll-like receptor 9 mediated responses in cardiac fibroblastsFatty Acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic strokeThe peripheral blood mononuclear cell microRNA signature of coronary artery disease.The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure.Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Increased levels of inflammatory cytokines and endothelin-1 in alveolar macrophages from patients with chronic heart failure.Efficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: a randomized controlled pilot studyPredictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study.Systemic biomarkers of inflammation and haemostasis in patients with chronic necrotizing pulmonary aspergillosis
P50
Q24626094-3A5011D4-94F0-478C-B20B-22D886383563Q24799394-4CD7FC45-2D0D-475B-8E71-197A7FB08948Q28083548-EE2DA5FD-48AF-47E6-A59B-392EDF8F965CQ28195974-15253C8C-51E5-49CE-870F-952BB7255E73Q28200764-11EE47CE-9666-45EC-A72C-9CF03A5D7930Q28261811-93589553-E603-406F-9D32-645B0A57F3EDQ28285454-8EF4DD8C-45CC-4D7E-8C33-3581CF957844Q28541982-0D10CEB3-2EE6-4712-8924-3F08E0ED7CDAQ28575465-86018C04-A0E9-415B-9B09-F973D23CA951Q28729147-9A6B1B31-F7D4-48BE-8CFF-805DC4491F71Q30405122-41B9C459-9F9E-46A7-B6EF-20D7F135BA06Q30587543-9EFD97D8-EF67-42D6-8ED2-A41C0F0EAF63Q30611192-FAEBBCB9-9FC3-4AF9-A9D7-F386DD2ACD67Q30873807-807D2B0C-214E-4C9A-947D-AFB877E5610FQ31111834-D4B28E3D-C4E4-4892-AA8E-C9CD33B7ECEBQ31152172-8217950C-0B6C-45C9-98E4-1730A57BB883Q32023336-3B395E4B-9824-45A7-A31B-099F0AE9A074Q32025738-84ECC80C-BA62-4F9B-8C87-4EDA1DFB9D62Q32055041-F002E429-F081-44FD-AB63-EA3E1441EAB1Q32083263-D2B51CB4-F7F7-4D45-A536-23BF741F4690Q33383387-01C7F3B5-8B94-46A4-8144-8C66D348AE14Q33522307-2CC4B2D6-8A85-4301-93A9-47192AA4ABF9Q33589324-8322EFC8-3E74-4540-96F1-AD311F9579B3Q33604761-8428E40E-C204-4D29-B78A-859F960AA709Q33632677-7EC8A08F-48FB-4F45-9BBC-A1DF59E629A6Q33731986-F7CB5E9D-57B2-4994-9EF8-123B42F5FD2AQ33788258-0855F9B9-FE21-4297-A85E-D0F6B4BDDA99Q33791924-8F267E0D-0E68-454B-934F-6DC01AAF6885Q33799421-A5612039-5ACA-435B-84F3-66401F925899Q33886486-B33EA7DC-D413-4E67-981D-F0102D5F58D1Q34025504-C4F9ACF4-FDAD-411A-AD66-DB8228551EA4Q34050642-F96E0867-ACC8-44BD-AAED-AC2BF76E805FQ34103370-3EA6EA7C-4E05-46A5-BA61-BD943469722FQ34104103-E3FA3415-B376-4B4F-AF94-EF12FDA75C25Q34200352-31E1FB67-3B74-4DD5-9E54-7712EDDAE8CEQ34269132-62D2B2D5-5986-4C9B-847B-1D26FCE032B0Q34277432-6BBA5F4A-14E8-4EDA-B6C6-B4C874EC5D13Q34277511-A1B5BCEF-491D-43B6-810D-E644885FA0D8Q34287563-2B8C367B-64FE-430C-A7C3-31D1D8DE61F8Q34316549-8E3F2E34-0067-40D0-9973-BFC8EDDA1862
P50
description
Noors onderzoeker
@nl
Norwegian professor
@en
norsk professor
@nb
ollamh Ioruach
@ga
name
Pål Aukrust
@ast
Pål Aukrust
@da
Pål Aukrust
@de
Pål Aukrust
@en
Pål Aukrust
@es
Pål Aukrust
@fr
Pål Aukrust
@ga
Pål Aukrust
@nb
Pål Aukrust
@nl
Pål Aukrust
@nn
type
label
Pål Aukrust
@ast
Pål Aukrust
@da
Pål Aukrust
@de
Pål Aukrust
@en
Pål Aukrust
@es
Pål Aukrust
@fr
Pål Aukrust
@ga
Pål Aukrust
@nb
Pål Aukrust
@nl
Pål Aukrust
@nn
prefLabel
Pål Aukrust
@ast
Pål Aukrust
@da
Pål Aukrust
@de
Pål Aukrust
@en
Pål Aukrust
@es
Pål Aukrust
@fr
Pål Aukrust
@ga
Pål Aukrust
@nb
Pål Aukrust
@nl
Pål Aukrust
@nn
P106
P21
P214
3112148997637459870001
P2287
P27
P31
P496
0000-0003-0919-836X
P5008
P569
1950-01-01T00:00:00Z
P734
P735
P7859
viaf-3112148997637459870001